BioMedNewsBreaks

FridayMay 21, 2021 3:00 pm

BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) Specialized Team Poised to Expand Doctor-to-Doctor, Consumer Sales

Healthy Extracts (OTCQB: HYEX) recently announced the addition of Dr. Joel Kahn, MD, to its medical board. Dr. Kahn, a world-renowned, triple board-certified cardiology specialist with 30 years of experience, has used BergametNA Citrus Bergamot SuperFruit(TM) on thousands of patients and approves the product’s cardiovascular health benefits. He has also personally conducted clinical studies that confirm the effectiveness of the superfruit, the main ingredient in BergametNA’s product line. HYEX CEO Duke Pitts noted that the company was delighted to welcome Dr. Kahn to its medical board. A recent article discussing this indicates that Pitts considers the addition of Dr. Kahn…

Continue Reading

ThursdayMay 20, 2021 12:16 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent article regarding Tryp’s positioning. The piece also discusses the company’s three strategic initiatives. “Develop” is its first initiative, under which Tryp intends to utilize FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.…

Continue Reading

ThursdayMay 20, 2021 12:12 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Presentation Schedule for June Investor Conferences

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two investor conferences slated to take place in June. These include scheduled presentations, as detailed in the update, at the Jefferies Virtual Healthcare Conference and the William Blair 41st Annual Virtual Growth Stock Conference. Interested parties should visit the sponsor’s conference website for more information regarding these events. To view the full press release, visit https://ibn.fm/lYl1b About VistaGen Therapeutics Inc. VistaGen is…

Continue Reading

ThursdayMay 20, 2021 11:45 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary Covid-ID Lab to Launch in Germany

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that Marx Pharma GmbH, the company’s distribution, storage and logistics partner, is launching Covid-ID Lab, XPhyto’s 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system in Germany; the product will launch on May 25. The announcement noted that the proprietary Covid-ID Lab will be priced within the range of commonly available COVID-19 PCR test products already on the market and that initial manufacturing capacity has been determined; additional manufacturing capacity is also available if needed. XPhyto’s Covid-ID Lab requires only a 20-minute PCR run…

Continue Reading

WednesdayMay 19, 2021 2:45 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Is Pushing Boundaries of What Is Possible in Neurology Research

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was recently featured in Neoscope (a publication by Futurism) as a company that champions cutting-edge research that is shaping the future in the field of brain diagnostics. “The article details Brain Scientific’s e-tattoo technology — a series of tiny electrodes stitched beneath the skin that can get a clear reading of neural signals in real-time,” reads a recent update regarding the company and its ground-breaking technology. “The feature reports that Brain Scientific is exploring possibilities to use big data collected through e-tattoo to study the neurological…

Continue Reading

WednesdayMay 19, 2021 10:24 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces On-Track Progress for Demonstration of i/Blue Imaging System(TM)

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early September. The product will showcase updates to meet performance criteria against competitive products and enhancements made to the design for manufacturing. “As the process moves forward, we’re creating the potential for additional IP that will…

Continue Reading

WednesdayMay 19, 2021 9:57 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Patient Enrollment in Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has begun open enrollment for its upcoming study focused on analyzing the efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (“GBM”). GMB is one of the most aggressive types of brain cancer, and Berubicin, which is in development for the treatment of several serious brain and CNS oncology indications, is the first anthracycline to cross the blood-brain barrier. CNSP plans on enrolling some 210 subjects across 35 clinical sites…

Continue Reading

TuesdayMay 18, 2021 3:13 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The discussion also highlighted Helomics’ innovative PeDAL (patient-centric drug discovery using active learning) platform. A unique technology, PeDAL combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and…

Continue Reading

TuesdayMay 18, 2021 2:59 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Eyes ‘Exceptional’ Work to Move i/Blue Imaging System(TM) into Commercial Manufacturing

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, was featured in a recent article that discussed its timely progress toward 2022 completion of its innovative i/Blue Imaging System(TM). The patented system is designed leveraging proprietary light sensors and optics to improve the efficiency and accuracy of bladder cancer visualization and removal. According to the update, the on-track progress can be largely attributed to the company’s selection of Lighthouse Imaging as its manufacturing partner. “Lighthouse’s development program is focused on refining the i/Blue system’s design to ensure that the final device complies with all regulatory standards while maintaining optimal…

Continue Reading

FridayMay 14, 2021 1:35 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to XPhyto’s customers in line with product specifications and relevant logistical and regulatory requirements in Germany. A recent article quotes XPhyto CEO and Director Hugh Rogers, who noted that the company had secured a strong partner…

Continue Reading